• bitcoinBitcoin(BTC)$64,938.001.72%
  • ethereumEthereum(ETH)$1,819.972.47%
  • tetherTether(USDT)$1.00-0.04%
  • binancecoinBNB(BNB)$592.851.27%
  • usd-coinUSDC(USDC)$1.00-0.01%
  • rippleXRP(XRP)$0.961.42%
  • solanaSolana(SOL)$71.242.27%
  • tronTRON(TRX)$0.302929-0.94%
  • Figure HelocFigure Heloc(FIGR_HELOC)$1.06-0.87%
  • HyperliquidHyperliquid(HYPE)$66.522.84%
  • zcashZcash(ZEC)$898.690.69%
  • dogecoinDogecoin(DOGE)$0.0588912.70%
  • moneroMonero(XMR)$489.751.15%
  • USDSUSDS(USDS)$1.000.01%
  • leo-tokenLEO Token(LEO)$9.180.65%
  • whitebitWhiteBIT Coin(WBT)$62.881.64%
  • chainlinkChainlink(LINK)$9.161.64%
  • cardanoCardano(ADA)$0.1534752.93%
  • Ethena USDeEthena USDe(USDE)$1.00-0.01%
  • stellarStellar(XLM)$0.1391301.72%
  • RainRain(RAIN)$0.00683087.11%
  • daiDai(DAI)$1.00-0.01%
  • nearNEAR Protocol(NEAR)$3.192.55%
  • bitcoin-cashBitcoin Cash(BCH)$208.012.46%
  • litecoinLitecoin(LTC)$44.890.67%
  • CantonCanton(CC)$0.0837984.81%
  • avalanche-2Avalanche(AVAX)$7.170.45%
  • uniswapUniswap(UNI)$5.205.09%
  • tether-goldTether Gold(XAUT)$3,840.240.64%
  • USD1USD1(USD1)$1.000.04%
  • the-open-networkGram (prev. Toncoin)(GRAM)$1.061.24%
  • suiSui(SUI)$0.721.52%
  • Ripple USDRipple USD(RLUSD)$1.000.01%
  • Global DollarGlobal Dollar(USDG)$1.000.01%
  • paypal-usdPayPal USD(PYUSD)$1.000.00%
  • hedera-hashgraphHedera(HBAR)$0.0587273.67%
  • Ondo US Dollar YieldOndo US Dollar Yield(USDY)$1.15-0.04%
  • shiba-inuShiba Inu(SHIB)$0.0000040.90%
  • quant-networkQuant(QNT)$156.097.66%
  • BittensorBittensor(TAO)$190.852.63%
  • crypto-com-chainCronos(CRO)$0.042709-1.52%
  • Circle USYCCircle USYC(USYC)$1.140.00%
  • Spiko Amundi Overnight Swap Fund (EUR)Spiko Amundi Overnight Swap Fund (EUR)(EURSAFO)$1.12-0.06%
  • MemeCoreMemeCore(M)$0.822.30%
  • okbOKB(OKB)$85.780.70%
  • pax-goldPAX Gold(PAXG)$3,842.560.65%
  • aaveAave(AAVE)$109.554.89%
  • Falcon USDFalcon USD(USDF)$1.000.01%
  • BlackRock USD Institutional Digital Liquidity FundBlackRock USD Institutional Digital Liquidity Fund(BUIDL)$1.000.00%
  • United StablesUnited Stables(U)$1.00-0.04%
TradePoint.io
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop
No Result
View All Result
TradePoint.io
No Result
View All Result

CVS says GLP-1s save money when priced below $350 per month

November 15, 2026
in Business
Reading Time: 4 mins read
A A
CVS says GLP-1s save money when priced below 0 per month
ShareShareShareShareShare

CVS Health said employers and other health plan sponsors could break even on GLP-1 drugs if they are priced below $350 per month as reduced use of medical services, such as hospitalizations and emergency room visits, lower spending enough to offset drug costs.

CVS said that an analysis of its Aetna insurance claims data found that across patients with obesity, diabetes or other conditions, the current prices for GLP-1 drugs add to spending because they are too high to be impacted by lower medical costs.

YOU MAY ALSO LIKE

Jensen Huang’s allies pushing Nvidia board to re-appoint him days after he resigned over Chinese spy, employee affairs

US diesel below $6 a gallon at 2-month low on easing tensions, weaker demand

The analysis looked at patients who were newly taking highly popular GLP-1 medicines — which mimic the GLP-1 hormone and reduce appetite — from Eli Lilly and Novo Nordisk, and compared them to similar patients who were not taking the drugs.


CVS Health said lower-priced GLP-drugs could lead to savings for employers and other health plan sponsors through reduced use of medical services. dpa/picture alliance via Getty Images

The drugs included Mounjaro and Ozempic for diabetes and Zepbound and Wegovy for obesity. The analysis covered periods of up to three years, with patients starting the medicines between 2023 and 2025.

The analysis did not break out figures for obesity patients alone.

Coverage of GLP-1 drugs for obesity is falling as corporations and other health plan sponsors try to bring down premiums expected to be up by over 9% in 2027. About 14% of companies have already dropped or plan to drop the drugs in 2027.

Zepbound and Wegovy can cost about $299 and $349 for cash-pay customers. Employers and other health plan sponsors pay between $617 and $766 monthly for the drugs, according to a 2025 study by the Employee Benefit Research Institute. CVS declined to comment on the average prices paid.

Dr. Amy Compton-Phillips, chief medical officer at CVS Health, said that the drugmakers’ direct-to-consumer prices suggest they can still profit by charging less than $350 a month, while also helping to lower overall health care costs. The US pays more for health care than any other country.

“I hope that we can reach that price sooner rather than later,” she said in an interview ahead of the HLTH USA conference in Las Vegas, where CVS will present the findings on Sunday.


Illustration of the CVS Health logo.
GLP-1 use for obesity, diabetes or other conditions was associated with 10%-12% lower emergency room visits in the first and second year of use, according to CVS Health. REUTERS

The US government agreed on a deal with Lilly and Novo last year to pay $245 per month for injectable GLP-1 weight-loss drugs in an 18-month pilot testing their cost-effectiveness for Medicare beneficiaries aged 65 and older or with disabilities.

CVS said GLP-1 use for obesity, diabetes or other conditions was associated with 10%-12% lower emergency room visits in the first and second year of use. It examined records for 60,000 people during the first year and 20,000 people for a second year.

An analysis of records for 4,000 people still taking the drug after three years showed a decrease in hospitalizations of 34-42%, according to the report.

When looking at spending and savings across those three years, plan sponsors saved $9,400 per person on medical bills, but spent $13,300 more on prescriptions, adding costs of $3,900 per person.

The company, which also operates pharmacy benefit manager Caremark and a network of retail pharmacies it plans to spin off, said the price at which GLP-1s start saving money overall depends on how healthy or sick a patient is.

“An older person with diabetes is going to have a higher risk for hospitalization than a younger person who is obese without diabetes,” said Compton-Phillips. “The higher-risk the person is, the quicker you get to a return on investment.”

Credit: Source link

ShareTweetSendSharePin

Related Posts

Jensen Huang’s allies pushing Nvidia board to re-appoint him days after he resigned over Chinese spy, employee affairs
Business

Jensen Huang’s allies pushing Nvidia board to re-appoint him days after he resigned over Chinese spy, employee affairs

November 15, 2026
US diesel below  a gallon at 2-month low on easing tensions, weaker demand
Business

US diesel below $6 a gallon at 2-month low on easing tensions, weaker demand

November 15, 2026
Gary Barnett’s Extell on development rampage in Manhattan
Business

Gary Barnett’s Extell on development rampage in Manhattan

November 15, 2026
Binance targets full reopening of withdrawals by end of this week
Business

Binance targets full reopening of withdrawals by end of this week

November 15, 2026
Next Post
Which Is Actually Better For Your Ears?

Which Is Actually Better For Your Ears?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

No Result
View All Result
Steve Kornacki works through technical difficulties

Steve Kornacki works through technical difficulties

November 10, 2026
Deadly train crash in Spain marks second fatal rail disaster this year

Deadly train crash in Spain marks second fatal rail disaster this year

November 15, 2026
AbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

AbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

November 13, 2026

About

Learn more

Our Services

Legal

Privacy Policy

Terms of Use

Bloggers

Learn more

Article Links

Contact

Advertise

Ask us anything

©2020- TradePoint.io - All rights reserved!

Tradepoint.io, being just a publishing and technology platform, is not a registered broker-dealer or investment adviser. So we do not provide investment advice. Rather, brokerage services are provided to clients of Tradepoint.io by independent SEC-registered broker-dealers and members of FINRA/SIPC. Every form of investing carries some risk and past performance is not a guarantee of future results. “Tradepoint.io“, “Instant Investing” and “My Trading Tools” are registered trademarks of Apperbuild, LLC.

This website is operated by Apperbuild, LLC. We have no link to any brokerage firm and we do not provide investment advice. Every information and resource we provide is solely for the education of our readers. © 2020 Apperbuild, LLC. All rights reserved.

No Result
View All Result
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop

© 2023 - TradePoint.io - All Rights Reserved!